Skip to main content

ADVERTISEMENT

Alexander Spira, MD, PhD

Alexander Spira, MD, PhD
Videos
09/13/2023
Alexander Spira, MD, PhD, discusses updated results from the CHRYSALIS-2 study, in which amivantamab and lazertinib plus chemotherapy demonstrated durable and meaningful responses among patients with EGFR-mutated NSCLC, as presented at the...
Alexander Spira, MD, PhD, discusses updated results from the CHRYSALIS-2 study, in which amivantamab and lazertinib plus chemotherapy demonstrated durable and meaningful responses among patients with EGFR-mutated NSCLC, as presented at the...
Alexander Spira, MD, PhD,...
09/13/2023
Oncology
Alexander Spira, MD, PhD
Videos
09/13/2023
Alexander Spira, MD, PhD, discusses the efficacy of amivantamab among patients with METex14 NSCLC enrolled in the CHRYSALIS study, as presented at the 2023 World Conference on Lung Cancer.
Alexander Spira, MD, PhD, discusses the efficacy of amivantamab among patients with METex14 NSCLC enrolled in the CHRYSALIS study, as presented at the 2023 World Conference on Lung Cancer.
Alexander Spira, MD, PhD,...
09/13/2023
Oncology
Alexander Spira, MD, PhD
Videos
09/26/2024
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD,...
09/26/2024
First Report Managed Care
Alexander Spira, MD, PhD
Videos
09/26/2024
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD,...
09/26/2024
Journal of Clinical Pathways